Search research articles
Contact Us
Filters
Showing results (331-340 of 350) with videos related to
Page
of 35
Sort By:
Annals of Translational Medicine
|
December 24, 2015
Chinese guidelines on the management of renal cell carcinoma (2015 edition)
Jun Guo, Jianhui Ma, Yan Sun, et al.
Chinese Clinical Oncology
|
March 3, 2016
Chinese guidelines on the management of renal cell carcinoma (2015 edition)
Jun Guo, Jianhui Ma, Yan Sun, et al.
Alimentary Pharmacology & Therapeutics
|
April 1, 2022
Corticosteroid plus glycyrrhizin therapy for chronic drug- or herb-induced liver injury achieves biochemical and histological improvements: a randomised open-label trial
Jia-Bo Wang, Ang Huang, Yijin Wang, et al.
The Lancet Regional Health. Western Pacific
|
June 7, 2023
Safety and immunogenicity of an
Kai Chu, Zhao-Feng Bi, Wei-Jin Huang, et al.
The Lancet Regional Health. Western Pacific
|
September 8, 2025
Immunogenicity comparison of an <i>Escherichia coli</i>-produced 9-valent human papillomavirus vaccine and Gardasil9 in Chinese women aged 18-26 years: three-year follow-up data from a randomised clinical trial
Guo-Hua Zhong, Zhao-Feng Bi, Kai Chu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 29, 2021
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
Shukui Qin, Feng Bi, Shanzhi Gu, et al.
JAMA Network Open
|
June 15, 2026
Adjuvant Chemoradiotherapy or Chemotherapy After D2 Gastrectomy in Gastric Cancer: A Randomized Clinical Trial
Xin Wang, Ouying Yan, Jitao Zhou, et al.
Journal of Hematology & Oncology
|
November 12, 2024
Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II trial
Feng Bi, Jian Dong, Chuan Jin, et al.
The Lancet. Infectious Diseases
|
July 20, 2023
Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18-26 years in China: a randomised blinded clinical trial
Feng-Cai Zhu, Guo-Hua Zhong, Wei-Jin Huang, et al.
Science Bulletin
|
September 24, 2023
Immunogenicity and safety of an Escherichia coli-produced human papillomavirus (types 6/11/16/18/31/33/45/52/58) L1 virus-like-particle vaccine: a phase 2 double-blind, randomized, controlled trial
Yue-Mei Hu, Zhao-Feng Bi, Ya Zheng, et al.
Page
of 35
Search research articles
Search
Showing results (331-340 of 350) with videos related to
Sort By:
Page
of 35
Annals of Translational Medicine
|
December 24, 2015
Chinese guidelines on the management of renal cell carcinoma (2015 edition)
Jun Guo, Jianhui Ma, Yan Sun, et al.
Chinese Clinical Oncology
|
March 3, 2016
Chinese guidelines on the management of renal cell carcinoma (2015 edition)
Jun Guo, Jianhui Ma, Yan Sun, et al.
Alimentary Pharmacology & Therapeutics
|
April 1, 2022
Corticosteroid plus glycyrrhizin therapy for chronic drug- or herb-induced liver injury achieves biochemical and histological improvements: a randomised open-label trial
Jia-Bo Wang, Ang Huang, Yijin Wang, et al.
The Lancet Regional Health. Western Pacific
|
June 7, 2023
Safety and immunogenicity of an
Kai Chu, Zhao-Feng Bi, Wei-Jin Huang, et al.
The Lancet Regional Health. Western Pacific
|
September 8, 2025
Immunogenicity comparison of an <i>Escherichia coli</i>-produced 9-valent human papillomavirus vaccine and Gardasil9 in Chinese women aged 18-26 years: three-year follow-up data from a randomised clinical trial
Guo-Hua Zhong, Zhao-Feng Bi, Kai Chu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 29, 2021
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
Shukui Qin, Feng Bi, Shanzhi Gu, et al.
JAMA Network Open
|
June 15, 2026
Adjuvant Chemoradiotherapy or Chemotherapy After D2 Gastrectomy in Gastric Cancer: A Randomized Clinical Trial
Xin Wang, Ouying Yan, Jitao Zhou, et al.
Journal of Hematology & Oncology
|
November 12, 2024
Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II trial
Feng Bi, Jian Dong, Chuan Jin, et al.
The Lancet. Infectious Diseases
|
July 20, 2023
Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18-26 years in China: a randomised blinded clinical trial
Feng-Cai Zhu, Guo-Hua Zhong, Wei-Jin Huang, et al.
Science Bulletin
|
September 24, 2023
Immunogenicity and safety of an Escherichia coli-produced human papillomavirus (types 6/11/16/18/31/33/45/52/58) L1 virus-like-particle vaccine: a phase 2 double-blind, randomized, controlled trial
Yue-Mei Hu, Zhao-Feng Bi, Ya Zheng, et al.
Page
of 35